Vita means life. It's also our platform for sharing the stories of biotech's promise to patients and public health.
CSL consists of CSL Behring, CSL Seqirus and CSL Vifor. Learn more by visiting each section.
Biotechnology leader CSL Behring offers the broadest range of quality plasma-derived and recombinant therapies in our industry.
Derived from the expression 'securing health for all of us', CSL Seqirus is one of the world's largest influenza vaccine providers.
R&D focuses its expertise on four strategic platforms: plasma protein technology; recombinant technology; cell and gene therapy; and vaccines technology.
One of our core values at CSL is Innovation. We support collaborative innovation through the endowment of awards and grants to researchers around the world.
As part of our broader sustainability strategy to build a more sustainable future, we've committed to a 40% reduction in absolute Scope 1 and 2 emissions by 2030.
Along with our sustainability strategy, CSL’s community contribution framework helps deliver on our Values and support execution of our 2030 strategy.
At CSL, Diversity, Equity, and Inclusion (DEI) is at the core of our mission and who we are. It fuels our innovation day in and day out.
Whether you are early in your college education or recently completed your degree, it's never too soon to consider CSL for your Promising Future!
A Duke University expert recommends primary immunodeficiency patients take steps to protect themselves this holiday season. R…
For the immunocompromised, wearing a mask in 2023 can invite comments and criticism. Here are three tips for handling pushbac…
CSL’s vaccine manufacturing capability in Australia is featured in a new exhibit at London’s Science Museum that revisits the…
5 ways to stay healthy as the winter holidays approach, bringing family togetherness, office parties and some familiar uncert…
Get 3 tips from an immunologist for how to manage fall and winter 2022.
To stay well, experts recommend both a flu shot and a new, revamped vaccine against COVID-19.
Patients who have primary immunodeficiencies could be more at risk of long COVID, a researcher recently told the Immune Defic…
Krissy is raising a son, now a teen, who has hemophilia. Hear her words of encouragement.
With little choice during the pandemic, many patients adjusted to virtual visits. Now they’re likely here to stay due to conv…
U.S. medical experts authorize an additional booster for some people with immune system problems to keep their defenses up ag…
Research found slightly more than half of HAE patients who had COVID-19 experienced a swelling attack while infected.
Lean into the momentum and innovation that the global pandemic inspired, CSL CEO Paul Perreault told attendees of The Economi…
Americas
Asia Pacific
Middle East
Europe
